Drug intelligence / Profile preview

89Zr-Lumi804-anti-LHRH + 177Lu-Lumi804-anti-LHRH

Development stage: Preclinical
Lead developer: Lumiphore
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

89Zr-Lumi804-anti-LHRH + 177Lu-Lumi804-anti-LHRH is a preclinical radiotheranostic pair developed by Lumiphore for the management of prostate cancer. This matched pair consists of an anti-LHRH monoclonal antibody conjugated to Lumiphore's proprietary Lumi804 macrocyclic chelator, which is an octadentate ligand based on hydroxypyridinone coordinating units. The diagnostic component is labeled with Zirconium-89 (89Zr) for positron emission tomography (PET) imaging, while the therapeutic component is labeled with Lutetium-177 (177Lu) for targeted beta-radiation therapy. Both conjugates target the luteinizing hormone-releasing hormone (LHRH) receptor, which is frequently overexpressed in prostate cancer cells. This theranostic approach allows for personalized treatment by using the imaging agent to identify patients with high target expression and to monitor the distribution and efficacy of the subsequent therapeutic dose.

Other names: Lumi804™-Anti-LHRH (Zr-89 imaging / Lu-177 therapy)Zr-89-Lumi804 anti-LHRHZr89-Lumi804 anti-LHRHZr 89-Lumi804 anti-LHRHLu-177-Lumi804 anti-LHRHLu177-Lumi804 anti-LHRHLu 177-Lumi804 anti-LHRH

Targets

GnRHR (Gonadotropin-releasing hormone receptor)

Beyond the preview

Go deeper on 89Zr-Lumi804-anti-LHRH + 177Lu-Lumi804-anti-LHRH.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 89Zr-Lumi804-anti-LHRH + 177Lu-Lumi804-anti-LHRH.

Explore the full profile